title: Inhibitory effect of prostaglandin E 1 on intimal thickening caused by poor runoff conditions in the canine autologous vein grafts.
abstract: The efficacy of ONO-1608, a newly developed liposomal formulation of prostaglandin E 1 prodrug, was evaluated on intimal hyperplasia of experimental canine autologous vein grafts under distal poor runoff conditions. The femoral vein was implanted into the femoral artery, preparing a distal poor runoff canine model. After 4 weeks of preparing the poor runoff model, the femoral vein was implanted into the femoral artery. They were then divided into two groups consisting of the control group and the ONO-1608 group. At 4 weeks, the grafts were harvested and intimal hyperplasia of the graft was measured with an ocular cytometer. Intimal cell proliferation was determined by bromodeoxyuridine incorporation 2 weeks after surgery. In addition, the effect of ONO-1608 on the proliferation of platelet-derived growth factor (PDGF)-stimulated human aortic smooth muscle cells (HASMCs) in culture was also investigated. At 4 weeks, the degree of intimal hyperplasia of the graft in the ONO-1608 group was significantly less than that of the control group. The bromodeoxyuridine labeling index 2 weeks after grafting was significantly lower in the ONO-1608 group compared with that in the control group. In addition, ONO-1608 significantly inhibited the proliferation of PDGF-stimulated HASMCs in culture. These results demonstrate the efficacy of ONO-1608 in reducing the degree of intimal hyperplasia of canine autogenous vein grafts under poor runoff conditions. The mechanism of reducing the intimal hyperplasia may be that ONO-1608 inhibited PDGF-stimulated proliferation of the smooth muscle cell. These results suggest that the administration of ONO-1608 may be beneficial in patients who have undergone gone arterial reconstruction.
authors.affiliation: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. komori@surg2.med.kyushu-u.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Komori
authors.forename: T
authors.initials: T
authors.lastname: Furuyama
authors.forename: T
authors.initials: T
authors.lastname: Shoji
authors.forename: M
authors.initials: M
authors.lastname: Kume
authors.forename: E
authors.initials: E
authors.lastname: Mori
authors.forename: T
authors.initials: T
authors.lastname: Yamaoka
authors.forename: K
authors.initials: K
authors.lastname: Sugimachi
mesh_terms: D000527:Alprostadil / Q000494:pharmacology*; D000818:Animals; D001011:Aorta / Q000187:drug effects; D001973:Bromodeoxyuridine; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004285:Dogs; D005268:Femoral Vein / Q000637:transplantation*; D006801:Humans; D006965:Hyperplasia / Q000517:prevention & control; D023421:Models, Animal; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D010982:Platelet-Derived Growth Factor; D011355:Prodrugs / Q000494:pharmacology*; D013194:Staining and Labeling; D013997:Time Factors; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology
chemical_list: D010982:Platelet-Derived Growth Factor; D011355:Prodrugs; D000527:Alprostadil; D001973:Bromodeoxyuridine